Highlights on combination of pembrolizumab plus chemotherapy in metastatic triple-negative breast cancer: The KEYNOTE-355 study
ESMO 2021: The KEYNOTE-355 study
Share.
About Author
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
